Natural Capsules Earnings Call Transcript: Key Takeaways
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
Q2FY27 revenue ₹51.15 Cr (+12% YoY), EBITDA ₹3.01 Cr (5.88% margin), still PAT loss ₹4.22 Cr. Strategy: API scale-up, regulatory filings, CMO expansion.
NCL reported Q1FY27 revenue of ₹48.71 Cr (+8% Y-o-Y) with EBITDA at ₹1.12 Cr. Strategy focuses on scaling steroidal API volumes and HPMC line conversions to optimize capacity.
Natural Capsules Ltd reported Q4 FY26 revenue of ₹58.45cr (up 55% QoQ). Full-year FY26 revenue grew 11% to ₹187.20cr, though the company posted a net loss of ₹24.66cr.
Natural Capsules reports Q4FY26 revenue of ₹58.45 Cr (+30% Y-o-Y) while facing a PAT loss of ₹4.98 Cr. Strategy focuses on steroidal API scaling and HPMC capsule expansion.